Presentation is loading. Please wait.

Presentation is loading. Please wait.

ProjectFundingDescription (number of subjects)Main investigator, Coordinator, Key persons, ContactStatusInitiatedExpected to be completed 1. NORD-STAR.

Similar presentations


Presentation on theme: "ProjectFundingDescription (number of subjects)Main investigator, Coordinator, Key persons, ContactStatusInitiatedExpected to be completed 1. NORD-STAR."— Presentation transcript:

1 ProjectFundingDescription (number of subjects)Main investigator, Coordinator, Key persons, ContactStatusInitiatedExpected to be completed 1. NORD-STAR Swedish Medical Research SLL Medication provided by BMS and UCB Pharma Unrestricted funds Nordic randomized clinical trial in early RA. Initial 4-way randomization (conventional vs. 3 biologics); re-randomization for patients in remission to immediate vs. delayed step-down therapy. Appr. 3 year duration per patient (800 patients) Ronald van Vollenhoven, Maria Seddighzadeh, Camilla Gustafsson, Eleonore Nilsson, Peter Westerling, Melinda Mild, Nancy Vivar First patient in IV/ IRBIS-retrospectiveUnrestricted funds International registry (>400) Ronald van Vollenhoven, Melinda Mild, Anna Andersson, Retrospectively >400 patients have been registered; manuscript in preparation IRBIS-prospective GSK Unrestricted funds International prospective registry (Projected:2000) Ronald van Vollenhoven, Melinda Mild, Anna Andersson, Noémi Györi, Sara Linder The prospective registry was opened on March 10, 2012; 52 patients included CERERRAUnrestricted funds European registry collaboration (>3000) Katerina Chatzidionysiou Data on ca 3000 rituximab treated patients has been processed, 3 published articles, >6 presentations at EULAR and ACR RING trial (rituximab in SLE) Unrestricted funds European randomized clinical trial with rituximab in refractory SLE nephritis (200) Ronald van Vollenhoven, Fred Houssiau, Peter Westerling, Adrian Levitsky, Noémi Györi In preparation Rituxilup (rituximab in SLE) ARUK Unrestricted funds European randomized clinical trial with rituximab in new-onset SLE nephritis (200) Ronald van Vollenhoven, Liz Lightstone, Peter Westerling, Adrian Levitsky, Noémi Györi In preparation TREES (anti-CD20 in SLE) ARUK Unrestricted funds European randomized clinical trial with anti-CD20 in non-renal SLE (200) Ronald van Vollenhoven, Ian Bruce, Peter Westerling, Adrian Levitsky In preparation ULTRASOUND: Evaluation of diagnostic utility according to Bayes Unrestricted funds Swedish Collaboration Project (100) Hamed Rezaei, Yogan Kisten, Noémi Györi Ca 80 of 100 patients included; Poster EULAR MUSCARA: Ultrasound support in choice of therapy Abbott Prospective Swedish collaborative project (120) Hamed Rezaei, Peter Westerling, Erik af Klint, Yogan Kisten, Noémi Györi First patient in study February RHEUMASCAN: (fluorescence optical imaging) Feasibility study of new diagnostic tool Erik af Klint, Yogan Kisten, Noémi Györi, Anna Karlsson, Carolina Romanus SWEFOT 5-year follow-up 5-year clinical, radiological, and health-economic evaluation Ronald van Vollenhoven, Melinda Mild, Jonas Ericsson, Martin Neovius, Margareta Lindmark, Heather Miller, Adrian Levitsky, Noémi Györi, Nancy Vivar In preparation SWEFOT BiomarkersUnrestricted funds Biomarkers in early RA, in collaboration with Crescendo (487) Karen Hambardzumyan, Melinda Mild, Adrian Levitsky, Nancy Vivar Two poster presentations at EULAR SWEFOT PAMERA International GWAS collaboration through Mayo Clinic Ronald van Vollenhoven, Melinda Mild, Karen Hambardzumyan, Saedis Saevarsdottir, Leonid Padyukov DNA sent to Mayo Clinic, analyses in progress SWEFOT POPERAUnrestricted funds Predictive x-ray progression in early RA Ronald van Vollenhoven, Melinda Mild, Adrian Levitsky Poster at EULAR SWEFOT AdipokinesUnrestricted funds Adipokines in early RA, extension study Ronald van Vollenhoven, Kerstin Brismar, Melinda Mild, Adrian Levitsky, Karen Hambardzumyan, Anna Andersson, Inga-Lill Engvall, Nancy Vivar Adiponektin and leptin results available, IGF-1 pending. Analyses ongoing SWEFOT ACPA fine specificity Unrestricted funds Study of ACPA fine specificity as prediction marker Saedis Saevarsdottir, Melinda Mild, Alf Kastbom, Anna Andersson, Adrian Levitsky Ongoing SWEFOT Survivin Collaboration with Prof. Maria Bokarewa (Göteborg) Ronald van Vollenhoven, Maria Bokarewa, Melinda Mild, Karen Hambardzumyan, Adrian Levitsky Samples sent to Göteborg CELLCEPT in SLE and vasculitis Unrestricted funds Clinical chart review project (180) Cecilia Lourdudoss, Sanaa Jamil Completed Presented at CORA 2013; manuscript in preparation HCQ complianceUnrestricted funds International study (300) External, Cecilia Lourdudoss, Noémi Györi Enrollment to start during spring of Nutrition and therapy results in RA and SLE Unrestricted funds Registry study; PhD project (2000) Cecilia Lourdudoss Ongoing ADMIREAbbott Clinical Trial (32) Ronald van Vollenhoven, Katerina Chatzidionysiou, Eleonore Nilsson Trial completed Results presented at ACR 2012; manuscript in preparation DOSERAPfizer Clinical Trial (90) Ronald van Vollenhoven, Lara Dani, Seija Johansson Trial completed Results presented at ACR2012; manuscript in preparation ARTIS CZPUCB Pharma Certolizumab in RA, ARTIS registry study (400) Katerina.Chatzidionysiou Abstract EULAR 2012, Manuscript in preparation ARTIS Treatment sequences Unrestricted funds Treatment sequences with biologic drugs in RA (~2000) Katerina.Chatzidionysiou First data at ACR 2011 Manuscript in preparation TOCERRARoche European registries collaboration (2000) Katerina Chatzidionysiou, Cem Gabay In preparation Review health-economic registry studies in Nordic countries Literature review; PhD project Heather Miller Ongoing Health-economic studies of data from SWEFOT, DOSERA and other trials Health-economic data analysis and modeling; PhD project Heather Miller Planning stage Ultrasound in Psoriasis Pilot study Ronald van Vollenhoven, Mona Ståhle, Yogan Kisten, Hamed Rezaei, Noémi Györi Planning stage Request study Survey of infliximab treated patients Sanaa Jamil, Jenny RiazzoliStudy completed. Analyses ongoing Rituximab long-term follow up Follow-up of rituximab treated patients with SLE Sara Linder, Iva Gunnarsson, Noémi Györi Planning stage Rituximab B-cell markersSara Linder, Noémi Györi, Vivi Malmström, Louise BergPlanning stage PDA study Study of PDA use in adalimumab treated patients Ronald van Vollenhoven Study completed. Some analyses and publication remaining Ongoing and planned studies at ClinTRID


Download ppt "ProjectFundingDescription (number of subjects)Main investigator, Coordinator, Key persons, ContactStatusInitiatedExpected to be completed 1. NORD-STAR."

Similar presentations


Ads by Google